Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa infection in a murine burn wound model

Burns

Volumn 25, Issue 5, 1999, Pages 415-423

  Felts, A G ^b   Giridhar, G ^b   Grainger, D W ^a   Slunt, J B ^a  

^a GAMMA A Technologies Inc   (United States)

^b NONE

Author keywords

Antibodies; Burns; Wound infection

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN G; POLYCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BURN INFECTION; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; SURVIVAL; TOPICAL DRUG ADMINISTRATION;

ANIMALS; BURNS; FEMALE; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MICE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SURVIVAL RATE; WOUND INFECTION;

EID: 0032780589     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-4179(99)00017-0     Document Type: Article

References (46)

1. Greenfield E., McManus A.T. Infectious complications: Prevention and strategies for their control. Nurs Clin North Am. 32:1997;297-309.
2. Neely A.N., Miller R.G., Holder I.A. Proteolytic activity and fatal gram-negative sepsis in burned mice: Effect of exogenous proteinase inhibition. Infect Immun. 62:1994;2158-2164.
3. Yurt RW. Burns. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Disease, 4th ed. New York: Churchill Livingstone, 1995. p. 2761-2765.
4. Heggers J.P., McHugh T., Zoellner S., Boertman J.A., Niu X-T., Robson M.C., Velanovich V. Therapeutic efficacy of Timentin and Augmentin versus Silvadene in burn wound infections. J Burn Care Rehabil. 10:1989;421-424.
5. Frame J.D., Kangesu L., Malik W.M. Changing flora in burn and trauma units: Experience in the United Kingdom. J Burn Care Rehabil. 13:1992;281-286.
6. Ono Y., Kunii O., Suzuki H., Ikeda H., Kobayashi K., Kanegasaki S. Opsonic activity of sera and blister fluid from severely burned patients evaluated by a chemiluminescence method. Microbiol Immunol. 38:1994;373-377.
7. Yamamoto H., Siltharm S., De Serres S., Hultman C.S., Meyer A.A. Immediate burn wound excision restores antibody synthesis to bacterial antigen. J Surg Res. 63:1996;157-162.
8. Monafo W.W. Initial management of burns. N Eng J Med. 335:1996;1581-1586.
9. Dibirdik I., Durak N., Kislaoglu E., Kutluay T., Aytemiz C. Effects of prophylactic intravenous immunoglobulin-G therapy on humoral and cellular immune components and their functions in burned patients. Burns. 21:1995;130-135.
10. Neely A.N., Orloff M.M., Holder I.A., Healy D.P. Effect of thermal injury on the adherence of Candida albicans to murine splenic tissue. Infect Immun. 65:1997;3493-3495.
11. Neely A.N., Hoover D.L., Holder I.A., Cross A.S. Circulating levels of tumour necrosis factor, interleukin 6 and proteolytic activity in a murine model of burn and infection. Burns. 22:1996;524-530.
12. Hammarstrom L., Smith C.I.E. The use of intravenous IgG as prophylaxis and for treatment of infections. Infect. 18:1990;314-324.
13. Dwyer J.M. Manipulating the immune system with immune globulin. New Engl J Med. 326:1992;107-116.
14. Cometta A., Baumgartner J.D., Glauser M.P. Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients. Clin Exp Immunol. 97:(Suppl. 1):1994;69-72.
15. Herrod H.G. Use of intravenous immunoglobulin (IVIG) therapy in adults. Allergy Proc. 15:1994;309-312.
16. Duhem C., Dicato M.A., Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol. 97:(Suppl. 1):1994;79-83.
17. Cross AS. Intravenous immunoglobulins (IVIGs) to prevent and treat infectious diseases. In: Atassi MZ, Bixler GS, editors. Immunobiology of Proteins and Peptides VIII. New York: Plenum Press, 1995. p. 123-130.
18. Casadevall A., Scharff M.D. Return to the past: The case for antibody-based therapies in infectious diseases. Clin Infect Dis. 21:1995;150-161.
19. Neely A.N., Holder I.A., Larrick J.W., Chong L-T. Comparison of pre- versus post-sepsis treatment with polyclonal immunoglobulin vs O serotype specific monoclonal antibody in burned Pseudomonas aeruginosa infected mice. Serodiag Immunother. 4:1990;221-230.
20. Buckley R.H., Schiff R.I. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med. 325:1991;110-117.
21. Siber GR, Snydman DR. Use of immune globulins in the prevention and treatment of infections. In: Remington JS, Swartz MN, editors. Current Clinical Topics in Infectious Disease, vol. 12. Boston: Blackwell Scientific, 1992. p. 208-252.
22. Hiemstra P.S., Brands-Tajouiti J., van Furth R. Comparison of antibody activity against various microorganisms in intravenous immunoglobulin preparations determined by ELISA and opsonic assay. J Lab Clin Med. 123:1994;241-246.
23. 2 fragments administered intranasally. J Infect Dis. 173:1996;1123-1128.
24. Barekzi NA, Poelstra KA, Felts AG, Rojas IA, Slunt JB, Grainger DW. Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model. Antimicrob Agents Chemotherap 1998 (in press).
25. Stieritz D.D., Holder I.A. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model. J Infect Dis. 131:1975;688-691.
26. Zapata-Sirvent R., Hansbrough J.F. Cytotoxicity to human leukocytes by topical antimicrobial agents used for burn care. J Burn Care Rehabil. 14:1993;132-140.
27. McCauley R.L., Li Y-Y., Poole B., Evans M.J., Robson M.C., Heggers J.P., Herndon D.N. Differential inhibition of human basal keratinocyte growth to silver sulfadiazine and mafenide acetate. J Surg Res. 52:1992;276-285.
28. Price C.I., Horton J.W., Baxter C.R. Liposome delivery of aminoglycosides in burn wounds. Surg Gynecol Obstet. 174:1992;414-418.
29. McManus W.F., Goodwin C.W., Mason A.D., Pruitt B.A. Burn wound infection. J Trauma. 21:1981;753-756.
30. Smoot E.C., Kucan J.O., Graham D.R., Barenfanger J.E. Susceptibility testing of antibacterials against methicillin-resistant Staphylococcus aureus. J Burn Care Rehabil. 13:1992;198-202.
31. Tenover F.C. The best of times, the worst of times. The global challenge of antimicrobial resistance. Pharm World Sci. 17:1995;149-151.
32. Casadevall A. Crisis in infectious diseases: time for a new paradigm? Clin Infect Dis. 23:1996;790-794.
33. Sheridan R.L., Weber J., Benjamin J., Pasternack M.S., Tompkins R.G. Control of methicillin-resistant Staphylococcus aureus in a pediatric burn unit. Am J Infect Control. 22:1994;340-345.
34. Phillips L.G., Heggers J.P., Robson M.C. Burn and trauma units as sources of methicillin-resistant Staphylococcus aureus. J Burn Care Rehabil. 13:1992;293-297.
35. Holder I.A., Neely A.N. Fear of MRSA - Potential for future disaster. Burns. 24:1998;99-103.
36. Holder I.A., Neely A.N. Vancomycin resistant enterococci. Burns. 24:1998;389-391.
37. Ochi H, Ohtsuka H, Yokota S-I, Uezumi I, Terashima M, Irie K, Noguchi H. Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa Infect Immun 1991;550-554.
38. Feldman M, Bryan R, Rajan S, Scheffler L, Brunnert S, Tang H, Prince A. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection. Infect Immun 1998;43-51.
39. Holder I.A., Naglich J.G. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa; immunization using divalent flagella preparations. J Trauma. 26:1986;118-122.
40. Ottolini M.G., Hemming V.G., Piazza F.M., Johnson S.A., Darnell M.E.R., Prince G.A. Topical immunoglobulin is an effective therapy for Parainfluenza type 3 in a cotton rat model. J Infect Dis. 172:1995;243-245.
41. Graham B.S., Tang Y-W., Gruber W.C. Topical immunoprophylaxis of respiratory syncytial virus (RSV)-challenged mice with RSV-specific immune globulin. J Infect Dis. 171:1995;1468-1474.
42. Sherwood J.K., Zeitlin L., Whaley K.J., Cone R.A., Saltzman M. Controlled release of antibodies for long-term passive immunoprotection of female mice against genital herpes. Nature Biotechnol. 14:1996;468-471.
43. Baumgartner J.D., Glauser M.P. Controversies in the use of passive immunotherapy for bacterial infections in the critically ill patient. Rev Infect Dis. 9:1987;194-205.
44. Munster A.M., Moran K.T., Thupari J., Allo M., Winchurch R.A. Prophylactic intravenous immunoglobulin replacement in high-risk burn patients. J Burn Care Rehabil. 8:1987;376-380.
45. Holder I.A. Pseudomonas immunotherapy. Serodiag Immunother. 2:1988;7-16.
46. Childs C., Edwards-Jones V., Heathcote D.M., Dawson M., Davenport P.J. Patterns of Staphylococcus aureus colonization, toxin production, immunity and illness in burned children. Burns. 20:1994;514-521.